PL402987A1 - Enancjomer (1S, 2R) milnacypranu do wytwarzania leku - Google Patents

Enancjomer (1S, 2R) milnacypranu do wytwarzania leku

Info

Publication number
PL402987A1
PL402987A1 PL402987A PL40298704A PL402987A1 PL 402987 A1 PL402987 A1 PL 402987A1 PL 402987 A PL402987 A PL 402987A PL 40298704 A PL40298704 A PL 40298704A PL 402987 A1 PL402987 A1 PL 402987A1
Authority
PL
Poland
Prior art keywords
active
serotonin
noradrenaline
capture
enantiomer
Prior art date
Application number
PL402987A
Other languages
English (en)
Inventor
Jean Deregnaucourt
Richard Grosse
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32749596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL402987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of PL402987A1 publication Critical patent/PL402987A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Przedmiotem wynalazku jest (1S,2R) enancjomer milnacipranu (Z(±)-2-(aminometylo)-N,N-dietylo-1-fenylocyklopropano-karboksyamidu) lub jego farmaceutycznie dopuszczalna sól, do zastosowania jako lek przeznaczony do profilaktyki lub leczenia depresji, stanów depresyjnych, fibromialgii, zespolu przewleklego zmeczenia, bólu, u pacjentów z uprzednio stwierdzonymi i/lub wspólwystepujacymi chorobami ukladu krazenia, podawany w dawce mieszczacej sie w zakresie miedzy 0.01 mg i 10 mg/kg wagi ciala na dzien w jednej lub wiekszej ilosci porcji.
PL402987A 2003-02-14 2004-02-16 Enancjomer (1S, 2R) milnacypranu do wytwarzania leku PL402987A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301849A FR2851163B1 (fr) 2003-02-14 2003-02-14 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
US10/453,574 US7005452B2 (en) 2003-02-14 2003-06-03 Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug

Publications (1)

Publication Number Publication Date
PL402987A1 true PL402987A1 (pl) 2013-08-19

Family

ID=32749596

Family Applications (1)

Application Number Title Priority Date Filing Date
PL402987A PL402987A1 (pl) 2003-02-14 2004-02-16 Enancjomer (1S, 2R) milnacypranu do wytwarzania leku

Country Status (19)

Country Link
US (2) US7005452B2 (pl)
EP (1) EP2305225A1 (pl)
JP (2) JP4515446B2 (pl)
CN (1) CN1750817B (pl)
AT (1) ATE501716T1 (pl)
CY (1) CY1108287T1 (pl)
DE (1) DE602004031893D1 (pl)
DK (1) DK1908461T3 (pl)
ES (1) ES2359441T3 (pl)
FR (1) FR2851163B1 (pl)
HK (1) HK1115329A1 (pl)
IL (2) IL170117A (pl)
NZ (1) NZ575218A (pl)
PL (1) PL402987A1 (pl)
PT (1) PT1908461E (pl)
SI (1) SI1908461T1 (pl)
TN (1) TNSN05195A1 (pl)
UA (1) UA84697C2 (pl)
ZA (1) ZA200506566B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
PT1601349E (pt) * 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions
CN101014337A (zh) * 2004-07-22 2007-08-08 惠氏公司 治疗神经系统障碍和病症的方法
US7119211B2 (en) * 2004-09-23 2006-10-10 Yamakawa Chemical Industry Co., Ltd. Process for preparing optically active 3-(methylamino)-1-(2-thienyl) propan-1-ol and intermediates for preparation
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP1980271A4 (en) * 2006-01-27 2012-04-25 Asahi Kasei Pharma Corp MEDICINE FOR TRANSNASAL ADMINISTRATION
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
CN101195583B (zh) 2006-12-04 2012-07-04 四川抗菌素工业研究所有限公司 一种光学纯米那普仑及其盐的制备方法
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
EP2110129A1 (en) * 2008-04-18 2009-10-21 Pierre Fabre Medicament Use of enantiomer (1S, 2R) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
US20100197797A1 (en) * 2009-02-05 2010-08-05 Rao Srinivas G Methods of managing fibromyalgia using milnacipran
CA2779711C (en) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2011088331A1 (en) * 2010-01-14 2011-07-21 Forest Laboratories Holdings Limited Stable dosage forms of levomilnacipran
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
FR2978350B1 (fr) * 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
WO2015044962A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited Amorphous form of levomilnacipran hydrochloride and hydrates thereof
CN106928080B (zh) * 2015-12-31 2020-12-25 四川海思科制药有限公司 稠合环γ-氨基酸衍生物及其制备方法和在医药上的应用
CN109678747A (zh) * 2019-02-21 2019-04-26 南京恩泰医药科技有限公司 一种左旋米那普伦非对映异构体的制备方法
CN114128672B (zh) * 2021-11-21 2023-04-07 河南省儿童医院郑州儿童医院 一种孤独症大鼠模型的构建方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
JP2759906B2 (ja) 1990-05-08 1998-05-28 東芝タンガロイ株式会社 乾式焼結摩擦材料
JP2769290B2 (ja) 1994-03-31 1998-06-25 科学技術振興事業団 ミスト熱分解法によるセラミック微粉末の製造方法
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
FR2746314B1 (fr) 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
FR2759290B1 (fr) 1997-02-13 2004-06-18 Pf Medicament Minalcipran pour le traitement de l'incontinence urinaire
FR2759906B1 (fr) * 1997-02-21 2004-06-04 Pf Medicament Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
EP1077704A4 (en) * 1998-05-21 2002-01-30 Lilly Co Eli COMBINATION THERAPY FOR TREATING DEPRESSION
JP2002516282A (ja) * 1998-05-22 2002-06-04 イーライ・リリー・アンド・カンパニー 難治性鬱病の処置のための組合せ治療
JP2002516864A (ja) * 1998-05-29 2002-06-11 イーライ・リリー・アンド・カンパニー 両極性疾患の処置のための組合せ治療
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CN1660435A (zh) 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003068211A1 (en) 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
CA2500662A1 (en) 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy

Also Published As

Publication number Publication date
EP2305225A1 (fr) 2011-04-06
JP5431136B2 (ja) 2014-03-05
JP4515446B2 (ja) 2010-07-28
DK1908461T3 (da) 2011-05-16
IL201038A0 (en) 2010-05-17
HK1115329A1 (en) 2008-11-28
PT1908461E (pt) 2011-05-31
CN1750817B (zh) 2010-12-01
NZ575218A (en) 2010-07-30
CY1108287T1 (el) 2014-02-12
ATE501716T1 (de) 2011-04-15
FR2851163B1 (fr) 2007-04-27
JP2006517571A (ja) 2006-07-27
JP2010090143A (ja) 2010-04-22
CN1750817A (zh) 2006-03-22
IL201038A (en) 2015-05-31
ZA200506566B (en) 2006-05-31
ES2359441T3 (es) 2011-05-23
TNSN05195A1 (fr) 2007-06-11
USRE43879E1 (en) 2012-12-25
IL170117A (en) 2010-05-17
FR2851163A1 (fr) 2004-08-20
UA84697C2 (ru) 2008-11-25
US20040162334A1 (en) 2004-08-19
DE602004031893D1 (de) 2011-04-28
US7005452B2 (en) 2006-02-28
SI1908461T1 (sl) 2011-04-29

Similar Documents

Publication Publication Date Title
HK1079117A1 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
IL201038A0 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
AP2001002252A0 (en) Monoamine reuptake inhibitors for treatment of CNS disorders.
IL173062A0 (en) Substituted 2-aminotetralin for the treatment of depression
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
DOP2005000055A (es) Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos.
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
RU2008127882A (ru) Лечение пищевода барретта
DK1322305T3 (da) Anvendelse af R-arylpropionsyrer til fremstilling af lægemidler til behandling af lidelser af rheumatisk natur
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
TW200507853A (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
WO2008085872A8 (en) Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
SE0203778D0 (sv) A new oral immediated release dosage form
DE60336830D1 (de) Neue benzoylpiperidinverbindungen
SE9803155D0 (sv) A new composition
HUP0301863A2 (hu) Szorongásos megbetegedések gyógyítása szelektív norepinefrin visszavétel gátló hatású vegyületekkel

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)